Asia
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here’s a look.
Four months after collaborating on an experimental atopic dermatitis treatment, Amgen and Kyowa Kirin are seeing the fruits of that deal with positive Phase II data.
The U.S. FDA is kicking off the month of October with a number of PDUFA dates and an advisory committee meeting. Read on for more details.
It was a busy week for clinical trial news. Here’s a look.
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
The announcement came following independent FDA analyses of inspections conducted at the two CROs in November 2019.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The news sparked a mini-surge in shares of I-Mab, which were up 7.8% in pre-market U.S trading on September 28.
These life sciences companies are falling into some cold, hard investment cash.
PRESS RELEASES